HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis

Allogeneic Hematopoietic stem cell transplant (HSCT) remains the only curative treatment in patients with myelodysplastic syndrome (MDS). The reduction in transplant related mortality in recent years has expanded the applicability of transplant to older patients and those with co-morbidities. This is particularly relevant for patients with MDS who have a median age at diagnosis of 72 years. The introduction of reduced intensity regimens (RIC) and the improvement in donor availability has further contributed to an increase transplant numbers globally.

Source: Biology of Blood and Marrow Transplantation - August 30, 2018 Category: Hematology Authors: Marie Robin, Rapha ël Porcher, Annalisa Ruggeri, Didier Blaise, Christine Wolschke, Linda Koster, Emanuele Angelucci, Friedrich Stölzel, Victoria Potter, Ibrahim Yakoub-Agha, Yener Koc, Fabio Ciceri, Jürgen Finke, Hélène Labussière-Wallet, Maria Jes Source Type: research